within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BX20_RosuvastatinAndTelmisart;

model RosuvastatinAndTelmisart
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 600,
    Vdp = 0.5,
    k12 = 8.333333333333334e-06,
    k21 = 8.333333333333334e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>RosuvastatinAndTelmisartan</td></tr><tr><td>ATC code:</td><td>C10BX20</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>50</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rosuvastatin and telmisartan is a fixed-dose combination medication comprising rosuvastatin, a statin that lowers cholesterol by inhibiting HMG-CoA reductase, and telmisartan, an angiotensin II receptor blocker (ARB) used to control blood pressure. The fixed combination is intended for the treatment of patients with both hypercholesterolemia and hypertension. This combination is approved in some countries for co-management of cardiovascular risk factors.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic study reporting combined PK parameters for this fixed-dose combination was identified. Parameter estimates are based on known PK profiles of the individual components in healthy adult subjects.</p><h4>References</h4><ol><li><p>Son, M, et al., &amp; Park, K (2014). Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. <i>Clinical therapeutics</i> 36(8) 1147–1158. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2014.06.007\">10.1016/j.clinthera.2014.06.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24998012/\">https://pubmed.ncbi.nlm.nih.gov/24998012</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C10BX20 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end RosuvastatinAndTelmisart;
